Response to Letter on Semaglutide and Liver Health
Author Information
Author(s): Korakas Emmanouil, Kountouri Aikaterini, Pavlidis George, Oikonomou Evangelos, Vrentzos Emmanouil, Michalopoulou Eleni, Tsigkou Vasiliki, Katogiannis Konstantinos, Pliouta Loukia, Balampanis Konstantinos, Pililis Sotirios, Malandris Konstantinos, Tsapas Apostolos, Siasos Gerasimos, Ikonomidis Ignatios, Lambadiari Vaia
Primary Institution: National and Kapodistrian University of Athens
Conclusion
The study emphasizes the need for larger studies to assess the effects of GLP-1RAs on liver health in patients with type 2 diabetes.
Supporting Evidence
- The study highlights the need for further large-scale studies on GLP-1RAs and liver health.
- The pilot study included 10 patients in each treatment and control group.
- The primary outcome was the change in controlled attenuation parameter (CAP) score.
Takeaway
The authors are responding to comments about their study on a diabetes medication and its effects on liver health, saying more research is needed.
Methodology
The study involved a power calculation based on a pilot study with 10 patients in each group to determine the necessary sample size for detecting changes in liver health indicators.
Limitations
No structured dietary questionnaires were used, and patient compliance with exercise was not reported.
Participant Demographics
All participants had type 2 diabetes mellitus.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website